CARY, N.C., Aug. 8, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that it has rescheduled its release of ...
Earnings call Heron Therapeutics reported Q3 2025 revenue of $38.2M (+YoY), with Adjusted EBITDA of $1.5M. ZYNRELEF and APONVIE sales surged 49% and 173% YoY, respectively. Management reaffirmed FY25 ...
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2025 Earnings Call Transcript August 8, 2025 Heron Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.02 EPS, expectations were $-0.01.
Heron Therapeutics, Inc. (NASDAQ: HRTX) Q2 2025 Earnings Call Transcript August 8, 2025 Heron Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.02 EPS, expectations were $-0.01.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results